Baidu
map

Sci Transl Med:DNA血液化验可检测心脏移植排斥反应

2014-06-19 佚名 生物360

一种检测在心脏移植受者血液中循环的DNA差异的血液化验可用于诊断心脏移植排斥的可能性,并减少进行昂贵且侵入性心脏活检(它涉及移除部分心肌组织以进行分析的一种检查)的需要。这些发现或可减少移植病人所做的活检数,并最终用一种简单的血液化验来监控器官排斥以取代该有风险的检查。 Iwijn De Vlaminck及其同事研发出了一种通过测量在移植捐者与受者DNA序列中的细小差异来检测心脏移植排斥的无细胞D

一种检测在心脏移植受者血液中循环的DNA差异的血液化验可用于诊断心脏移植排斥的可能性,并减少进行昂贵且侵入性心脏活检(它涉及移除部分心肌组织以进行分析的一种检查)的需要。这些发现或可减少移植病人所做的活检数,并最终用一种简单的血液化验来监控器官排斥以取代该有风险的检查。

Iwijn De Vlaminck及其同事研发出了一种通过测量在移植捐者与受者DNA序列中的细小差异来检测心脏移植排斥的无细胞DNA化验。(无细胞DNA不是像大多数核酸那样位于细胞内,而是在血液中自由浮动的DNA。)研究人员收集了移植受者的血液样本,从中分离出其循环中的无细胞DNA(这是来自器官受者与捐者的混合DNA)并接着对其进行测序。利用捐者与受者DNA序列上存在的差异,研究人员能够确定来自捐者的DNA所占的比例。

此外,在一项前瞻性的临床研究中,他们发现,来自移植器官捐者的无细胞DNA浓度会在移植器官排斥事件之前几个星期开始增加。与其它用于检测移植器官排斥的非侵入性方法——例如基因表达谱(一种可观察基因表达中涉及免疫通路激活变化的工具)——不同,无细胞DNA检测是一种移植器官受损的高度特异性标记物。在该前瞻性试验中,它还能比目前可能的临床工具提前检测到(某些病人中的)器官排斥。

这些结果指出,无细胞DNA测试是一个比对移植病人进行心脏活检更好的选项。

原始出处:

Iwijn De Vlaminck, Hannah A. Valantine, Thomas M. Snyder, Calvin Strehl, Garrett Cohen, Helen Luikart,Norma F. Neff, Jennifer Okamoto, Daniel Bernstein, Dana Weisshaar, Stephen R. Quake,and Kiran K. Khush. Circulating Cell-Free DNA Enables Noninvasive Diagnosis of Heart Transplant Rejection. Sci Transl Med., 18 June 2014;

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2067145, encodeId=3007206e145c5, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Apr 05 16:47:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719575, encodeId=8d1e1e19575c5, content=<a href='/topic/show?id=72ce33606f6' target=_blank style='color:#2F92EE;'>#化验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33606, encryptionId=72ce33606f6, topicName=化验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54c932781196, createdName=wushaoling, createdTime=Sat Oct 04 02:47:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656611, encodeId=98361656611fb, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Sep 08 21:47:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262959, encodeId=713e1262959dd, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532129, encodeId=d83315321293d, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606214, encodeId=70fd160621410, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2067145, encodeId=3007206e145c5, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Apr 05 16:47:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719575, encodeId=8d1e1e19575c5, content=<a href='/topic/show?id=72ce33606f6' target=_blank style='color:#2F92EE;'>#化验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33606, encryptionId=72ce33606f6, topicName=化验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54c932781196, createdName=wushaoling, createdTime=Sat Oct 04 02:47:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656611, encodeId=98361656611fb, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Sep 08 21:47:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262959, encodeId=713e1262959dd, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532129, encodeId=d83315321293d, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606214, encodeId=70fd160621410, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
    2014-10-04 wushaoling
  3. [GetPortalCommentsPageByObjectIdResponse(id=2067145, encodeId=3007206e145c5, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Apr 05 16:47:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719575, encodeId=8d1e1e19575c5, content=<a href='/topic/show?id=72ce33606f6' target=_blank style='color:#2F92EE;'>#化验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33606, encryptionId=72ce33606f6, topicName=化验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54c932781196, createdName=wushaoling, createdTime=Sat Oct 04 02:47:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656611, encodeId=98361656611fb, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Sep 08 21:47:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262959, encodeId=713e1262959dd, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532129, encodeId=d83315321293d, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606214, encodeId=70fd160621410, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
    2014-09-08 bsmagic9140
  4. [GetPortalCommentsPageByObjectIdResponse(id=2067145, encodeId=3007206e145c5, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Apr 05 16:47:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719575, encodeId=8d1e1e19575c5, content=<a href='/topic/show?id=72ce33606f6' target=_blank style='color:#2F92EE;'>#化验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33606, encryptionId=72ce33606f6, topicName=化验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54c932781196, createdName=wushaoling, createdTime=Sat Oct 04 02:47:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656611, encodeId=98361656611fb, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Sep 08 21:47:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262959, encodeId=713e1262959dd, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532129, encodeId=d83315321293d, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606214, encodeId=70fd160621410, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2067145, encodeId=3007206e145c5, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Apr 05 16:47:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719575, encodeId=8d1e1e19575c5, content=<a href='/topic/show?id=72ce33606f6' target=_blank style='color:#2F92EE;'>#化验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33606, encryptionId=72ce33606f6, topicName=化验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54c932781196, createdName=wushaoling, createdTime=Sat Oct 04 02:47:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656611, encodeId=98361656611fb, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Sep 08 21:47:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262959, encodeId=713e1262959dd, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532129, encodeId=d83315321293d, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606214, encodeId=70fd160621410, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2067145, encodeId=3007206e145c5, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Apr 05 16:47:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719575, encodeId=8d1e1e19575c5, content=<a href='/topic/show?id=72ce33606f6' target=_blank style='color:#2F92EE;'>#化验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33606, encryptionId=72ce33606f6, topicName=化验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54c932781196, createdName=wushaoling, createdTime=Sat Oct 04 02:47:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656611, encodeId=98361656611fb, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Sep 08 21:47:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262959, encodeId=713e1262959dd, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532129, encodeId=d83315321293d, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606214, encodeId=70fd160621410, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 21 07:47:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]

相关资讯

FDA批准一小型左室辅助装置用于心衰患者

  2012年11月20日,美国食品与药物管理局(FDA)批准了HeartWare左心室辅助装置( LVAD)用于晚期心衰等待心脏移植的患者。   HeartWare  LVAD是由一个置入泵,外部驱动器以及电源组成,可于医院内或院外使用。   市场上其它的LVAD需要把部件埋在腹部,而HeartWare系统体积较小,可置入在患者胸部靠近心脏的地方,因此对体型较小

JACC:未来十年心脏移植研究方向

  美国国立心、肺、血液研究所(NHLBI)工作组讨论了心脏移植(HT)未来的研究方向。工作组由基础医学、临床医学和心力衰竭及心脏移植流行病学方面的专家组成。工作组成员评估了HT的关键领域,确定了最迫切的知识领域。文章发表于《美国心脏病学会杂志》(J Am Coll Cardiol, 2012; 59:1263-1269)。   这些领域总结为以下4个特定研究方向:①明确移植前人群的外在特征表现

Circ Res:心肌成纤维细胞或对治疗心脏疾病非常关键

长期以来,科学家们认为成纤维细胞对机体是无关紧要的,但近日,来自澳大利亚再生医学研究所的研究人员却表示,成纤维细胞或许对于心脏疾病患者的心脏移植非常关键,心肌成纤维细胞和心肌细胞非常相似,因此其或许对于开发治疗心脏疾病的疗法会带来帮助,相关研究刊登于国际杂志《Circulation Research》上。 研究者Furtado博士表示,由于遗传程序使得成心肌细胞变成了独特的细

Circulation:延长心脏移植生存的新型策略

  意大利一项研究表明,靶向离子通道嘌呤受体P2X7(P2X7R)是一种新型的延长心脏移植生存率的临床相关策略。该研究12月18日在线发表于《循环》(Circulation)杂志。   心脏移植对于终末期心力衰竭患者是一种挽救生命的方法。除了该领域的诸多进展,目前的免疫移植方案仍旧与长期不良心脏移植物转归及发生并发症包括感染和肿瘤等相关。发明新型、短期和有效的免疫调节疗法或可取得重要收获。细胞破

Eur Heart J:线粒体多态性或影响心脏移植预后

  来自西班牙的一项研究证实,线粒体单倍型类群可能是西班牙心脏移植人群终末期心衰进展的危险因素。此外,线粒体DNA(mtDNA)变异或对心脏移植并发症的发生造成一定影响。该研究2011年8月6日在线发表于《欧洲心脏杂志》(Eur Heart J)。   线粒体单倍型类群已知能够影响个体对广谱代谢性和退行性疾病的易感性,其中包括缺血性心血管疾病。研究评价了mtDNA背景对接受心

Baidu
map
Baidu
map
Baidu
map